Clinical trials such as CheckMate 459, KEYNOTE-224, and CheckMate 040 have presented consistent results supporting PD-L1 expression as a favorable biomarker for ICI-treated HCC (6, 20, 21). This evidence concerns the gene CD274 and hepatocellular carcinoma.